KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Adaptive Biotechnologies (ADPT) Equity Ratio (2018 - 2025)

Historic Equity Ratio for Adaptive Biotechnologies (ADPT) over the last 8 years, with Q3 2025 value amounting to 0.42.

  • Adaptive Biotechnologies' Equity Ratio rose 400.14% to 0.42 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.42, marking a year-over-year increase of 400.14%. This contributed to the annual value of 0.38 for FY2024, which is 1943.29% down from last year.
  • As of Q3 2025, Adaptive Biotechnologies' Equity Ratio stood at 0.42, which was up 400.14% from 0.36 recorded in Q2 2025.
  • Over the past 5 years, Adaptive Biotechnologies' Equity Ratio peaked at 0.68 during Q1 2021, and registered a low of 0.36 during Q2 2025.
  • Its 5-year average for Equity Ratio is 0.52, with a median of 0.52 in 2023.
  • Its Equity Ratio has fluctuated over the past 5 years, first soared by 822.3% in 2021, then plummeted by 2050.77% in 2024.
  • Adaptive Biotechnologies' Equity Ratio (Quarter) stood at 0.65 in 2021, then dropped by 17.18% to 0.54 in 2022, then decreased by 13.91% to 0.47 in 2023, then dropped by 19.43% to 0.38 in 2024, then increased by 10.88% to 0.42 in 2025.
  • Its Equity Ratio stands at 0.42 for Q3 2025, versus 0.36 for Q2 2025 and 0.37 for Q1 2025.